Skip to main content

Table 5 Selected clinical trials targeting cell surface proteins in triple negative breast cancer

From: Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications

Trial Target Treatment vs. control arm Phase Setting Key results
(Treatment vs. control)
Strategies targeting cell surface receptors
IMMU-132–01 [153] Trop-2 inhibitor
(Sacitizumab govitecan-hziy)
Sacitizumab govitecan-hziy I/II Heavily pretreated metastatic TNBC Objective response rate 33.3%
Median PFS 5.5 months
ASCENT [154] Trop-2 inhibitor
(Sacitizumab govitecan-hziy)
Sacitizumab govitecan-hziy vs. Chemotherapy III Heavily pretreated metastatic TNBC Median PFS
5.6 vs. 1.7 months
HR 0.41 (95%CI 0.32–0.52; P < 0.001)
NCT01969643 LIV-1
Inhibitor
(ladiratuzumab vedotin)
Ladiratuzumab vedotin I Advanced breast cancer Ongoing
Interim results: objective response rate of 32%
NCT03310957 LIV-1
Inhibitor
(ladiratuzumab vedotin)
 + PD1 inhibitor (pembrolizumab)
Ladiratuzumab vedotin
 + 
pembrolizumab
I/II Advanced TNBC Ongoing
Primary endpoint is objective response rate
Secondary endpoints include PFS and OS
DESTINY-Breast04
[162]
Trastuzumab-deruxtecan
(T-Dxd)
Trastuzumab-deruxtecan
vs
Chemotherapy (physician’s choice
III Pretreated Her2-low, unresectable and/or metastatic breast cancer Median PFS
9.9 vs. 5.1 months
HR 0.51 (95%CI 0.40–0.64; P < 0.001)
  1. Abbreviations: PFS progression free survival, OS overall survival, HR hazard ratio, CI confidence interval, TNBC triple negative breast cancer